A new clinical model for terminal idiopathic pulmonary fibrosis (IPF) that allows patients to receive treatment at home has increased patient satisfaction, decreased hospital deaths, led to better symptom management, and lowered healthcare costs. Those outcomes of this new clinical model were published recently in the journal NEJM…
New Clinical Model to Manage Terminally Ill IPF Patients Decreases Suffering and Costs
The Pulmonary Fibrosis Foundation (PFF) announced that its nationwide Care Center Network (CCN) now encompasses 68 medical centers in 33 states, following the addition of eight sites with recognized expertise in pulmonary fibrosis (PF) diagnosis, treatment,…
Following my diagnosis of idiopathic pulmonary fibrosis (IPF), I took some time to research the available information to learn about my disease. Despite discovering a lot of useful material from brochures, online sources, and support networks, I’ve found that connecting with other patients has helped me the most since my…
A patient with idiopathic pulmonary fibrosis (IPF), enrolled in the ZEPHYRUS Phase 3 clinical study, has been dosed with FibroGen’s investigational therapy pamrevlumab, the company announced. Still recruiting participants, the ZEPHYRUS study (NCT03955146) is expected to enroll approximately 565 IPF patients who have not responded to,…
The day after my mom, Holly, got on the transplant list, the doctor who had delivered the news said, “You’re at the top of the list. If we got lungs for you today, would you be ready?” It was scary to consider what stood between my mom and…
Increased activity of certain matrix metalloproteinases (MMPs), enzymes that regulate cell behavior, may explain the risk for developing aggressive pulmonary fibrosis in people with Hermansky-Pudlak syndrome (HPS), a rare genetic disorder, according to new research. The study highlights MMP-2 and MMP-9. The findings suggest that these unique…
Being diagnosed with a life-threatening illness and learning to live with it is not for the faint of heart. There is an abundance of emotions that accompanies a diagnosis plagued by a grim prognosis and no cure. No one can prepare you for how it feels to hear the words,…
Even before I was officially diagnosed with idiopathic pulmonary fibrosis (IPF), I could feel my health declining and my enthusiasm to complete yardwork diminishing. I always took great pride in my meticulously landscaped yard. When I moved into my wife’s house, I immediately tore up the yard, planted new…
Low levels of an enzyme associated with the rare childhood disorder sialidosis may lead to the development of idiopathic pulmonary fibrosis (IPF), according to new research. The findings also suggest that NEU1 enzyme levels may help in determining fibrosis’ risk and likely prognosis. The study “…
Boehringer Ingelheim will add Bridge Biotherapeutics’ experimental inhibitor BBT-877 to its portfolio of potential therapies for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). This follows the completion of a collaboration and global license agreement between the two companies for the development of BBT-877 for…
Your PF Community
Recommended Posts
- Study links new cell type to lung scarring in pulmonary fibrosis patients
- Recent health setbacks require us to find a more accessible home
- First global trial now testing new treatment for chronic cough in IPF
- Inhaled IPF therapy moves to Phase 2 as early trial shows promise
- Hopeful about the growing interest in IPF research and investment
